Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Zaragoza – page 41

549 clinical trials in Zaragoza, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Zaragoza at a glance
549
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

549 trials in Zaragoza

Open in trial search

Coronary artery disease

Not recruiting

Study on Reduced Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel for Patients with Coronary Artery Disease After Stent Implantation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Ivascular S.L.

Graves' disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Moderate-to-Severe Thyroid Eye Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic

Not recruiting

Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
  • Sponsor:Leo Pharma A/S

Leiomyosarcoma metastatic

Not recruiting

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Squamous cell carcinoma of head and neck

Not recruiting

Study of Tislelizumab, Surzebiclimab, and LBL-007 for Patients with Recurrent or Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LBL-007
  • Sponsor:BeOne Medicines AG

Colorectal adenocarcinoma

Not recruiting

Study on the Effectiveness and Safety of Cetuximab, Encorafenib, and Binimetinib for Patients with Advanced Colorectal Cancer with BRAF V600E Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Asthma

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Uncontrolled Asthma on Inhaled Corticosteroid and Long-Acting Beta2-Agonist Therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

HIV infection

Not recruiting

Study on Switching HIV Treatment to Dolutegravir/Lamivudine in Patients Aged 50+ with Virologic Suppression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Viiv Healthcare UK Limited

Hepatocellular carcinoma

Not recruiting

Study on Hepatocellular Carcinoma: Evaluating Livmoniplimab and Budigalimab for Patients with Advanced or Metastatic Cancer After First-Line Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Actinic keratosis

Not recruiting

Study on the Effectiveness and Safety of Tirbanibulin Ointment for Adults with Actinic Keratosis on the Face or Scalp

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tirbanibulin
  • Sponsor:Almirall S.A.

Chronic obstructive pulmonary disease

Not recruiting

Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aclidinium Bromide
  • Sponsor:Fundacio Privada Mon Clinic Barcelona

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Zaragoza

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focusing on advanced cancer treatments and blood disorders, including studies of new therapies for lung cancer, pancreatic adenocarcinoma, and various hematologic malignancies.

  • Non-small cell lung cancer treatments
  • Chronic lymphocytic leukemia therapies
  • Soft tissue sarcoma management

Multiple trials evaluating combination therapies and novel treatment approaches for both solid tumors and blood cancers.

02 Autoimmune & Inflammatory Conditions

Research into treatments for various inflammatory and autoimmune disorders, with emphasis on chronic conditions affecting quality of life.

  • Plaque psoriasis treatments
  • Crohn's disease management
  • Thyroid eye disease therapies

Studies focusing on innovative biological therapies and targeted treatments for inflammatory conditions.

03 Cardiovascular & Metabolic Disorders

Studies addressing critical cardiovascular health challenges and metabolic conditions, including innovative approaches to stroke treatment and lipid management.

  • Acute cerebral ischemic stroke
  • Hypertriglyceridemia treatments
  • Cardiovascular disease prevention

Focus on developing new therapeutic options for both acute and chronic cardiovascular conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.